

Synaptic ApS

Skt. Knuds Gade 20, st., 5000 Odense C

CVR no. 39 74 61 66

Annual report 2022

Approved at the Company's annual general meeting on 30 May 2023

Chair of the meeting:

.....
Eivind Antonsen Segtnan

Contents

<i>Statement by the Board of Directors and the Executive Board</i>	2
<i>Independent auditors' report on the compilation of financial statements</i>	3
<i>Management's review</i>	4
<i>Financial statements 1 January - 31 December</i>	6
Income statement	6
Balance sheet	7
Statement of changes in equity	9
Notes to the financial statements	10

Statement by the Board of Directors and the Executive Board

Today, the Executive Board has discussed and approved the annual report of Synaptic ApS for the financial year 1 January - 31 December 2022.

The annual report, which has not been audited, has been prepared in accordance with the provisions of the Danish Financial Statements Act. The Executive Board has considered the criteria for omission of audit to be met.

In my opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2022 and of the results of the Company's operations for the financial year 1 January - 31 December 2022.

Further, in my opinion, the Management's review gives a fair review of the matters discussed in the Management's review.

I recommend that the annual report be approved at the annual general meeting.

Odense, 30 May 2023
Executive Board:

Eivind Antonsen Segtnan
Managing director

Independent auditor's report on the compilation of financial statements

To the general management of Synaptic ApS

We have compiled the financial statements of Synaptic ApS for the financial year 1 January - 31 December 2022 based on the Company's bookkeeping and other information provided.

The financial statements comprise an income statement, balance sheet, statement of changes in equity and notes, including accounting policies.

We performed this compilation engagement in accordance with ISRS 4410 *Compilation Engagements*.

We have applied our expertise in accounting and financial reporting to assist you in the preparation and presentation of the financial statements in accordance with the Danish Financial Statements Act. We have complied with relevant requirements in the Danish Auditors Act and International Ethics Standards Board for Professional Accountants' International Code of Ethics for Professional Accountants (IESBA Code), including principles of integrity, objectivity, professional competence and due care.

The financial statements and the accuracy and completeness of the information used to compile the financial statements are your responsibility.

Since a compilation engagement is not an assurance engagement, we are not required to verify the accuracy or completeness of the information you provided to us to compile the financial statements. Accordingly, we do not express an audit opinion or a review conclusion on whether the financial statements are prepared in accordance with the Danish Financial Statements Act.

Odense, 30 May 2023
EY Godkendt Revisionspartnerselskab
CVR no. 30 70 02 28

Søren Smedegaard Hvid
State Authorised Public Accountant
mne31450

Management's review

Company details

Name	Synaptic ApS
Address, Postal code, City	Skt. Knuds Gade 20, st., 5000 Odense C
CVR no.	39 74 61 66
Established	26 July 2018
Registered office	Odense
Financial year	1 January - 31 December
Executive Board	Eivind Antonsen Segtnan, Managing director

Management's review

Business review

Synaptic is a research and development company in the pharmaceutical industry. The company's main activity is development and research within brain research and "individual-grouped testing" of viruses.

Recognition and measurement uncertainties

Development projects comprise of development cost for new technology and products. The recognition of the development projects has been made on the basis of sales forecasts which management expects to realize. The sales forecasts are subject to some uncertainty as the Company and its projects are in a start-up phase.

Financial review

The income statement for 2022 shows a profit of DKK 296,459 against a loss of DKK 50,325 last year, and the balance sheet at 31 December 2022 shows equity of DKK 157,964.

Events after the balance sheet date

No events materially affecting the Company's financial position have occurred subsequent to the financial year-end.

Financial statements 1 January - 31 December

Income statement

Note	DKK	2022	2021
	Other operating income	851,662	296,654
	Other external expenses	-562,150	-392,060
	Gross profit	289,512	-95,406
3	Staff costs	-17,626	0
	Amortisation/depreciation of intangible assets	-5,000	-5,000
	Profit/loss before net financials	266,886	-100,406
	Financial expenses	-95,172	-20,314
	Profit/loss before tax	171,714	-120,720
4	Tax for the year	124,745	70,395
	Profit/loss for the year	296,459	-50,325

Recommended appropriation of profit/loss

Other statutory reserves	548,185	469,541
Retained earnings/accumulated loss	-251,726	-519,866
	296,459	-50,325

Financial statements 1 January - 31 December

Balance sheet

Note	DKK	2022	2021
ASSETS			
<i>Fixed assets</i>			
5 <i>Intangible assets</i>			
Patents		417,780	282,000
Development projects in progress and prepayments for intangible assets		886,997	319,975
		<u>1,304,777</u>	<u>601,975</u>
<i>Investments</i>			
Deposits, investments		6,200	6,200
		<u>6,200</u>	<u>6,200</u>
<i>Total fixed assets</i>			
		<u>1,310,977</u>	<u>608,175</u>
<i>Non-fixed assets</i>			
<i>Receivables</i>			
Corporation tax receivable		124,745	70,395
Other receivables		146,829	36,334
		<u>271,574</u>	<u>106,729</u>
<i>Cash</i>			
		<u>29,644</u>	<u>468,499</u>
<i>Total non-fixed assets</i>			
		<u>301,218</u>	<u>575,228</u>
<i>TOTAL ASSETS</i>			
		<u>1,612,195</u>	<u>1,183,403</u>

Financial statements 1 January - 31 December

Balance sheet

Note	DKK	2022	2021
EQUITY AND LIABILITIES			
<i>Equity</i>			
Share capital		50,000	50,000
Reserve for development costs		1,017,726	469,541
Retained earnings		-909,762	-658,036
Total equity		157,964	-138,495
<i>Liabilities other than provisions</i>			
6 <i>Non-current liabilities other than provisions</i>			
Payables to shareholders and Management		242,912	538,628
Other payables		1,151,071	677,750
		1,393,983	1,216,378
<i>Current liabilities other than provisions</i>			
Trade payables		45,059	88,020
Other payables		15,189	17,500
		60,248	105,520
Total liabilities other than provisions		1,454,231	1,321,898
TOTAL EQUITY AND LIABILITIES		1,612,195	1,183,403

- 1 Accounting policies
- 2 Going concern uncertainties
- 3 Staff costs
- 7 Contractual obligations and contingencies, etc.
- 8 Collateral

Financial statements 1 January - 31 December

Statement of changes in equity

<i>DKK</i>	<i>Share capital</i>	<i>Reserve for development costs</i>	<i>Retained earnings</i>	<i>Total</i>
Equity at 1 January 2021	50,000	0	-138,170	-88,170
Transfer through appropriation of loss	0	469,541	-519,866	-50,325
Equity at 1 January 2022	50,000	469,541	-658,036	-138,495
Transfer through appropriation of profit	0	548,185	-251,726	296,459
Equity at 31 December 2022	50,000	1,017,726	-909,762	157,964

Financial statements 1 January - 31 December

Notes to the financial statements

1 Accounting policies

The annual report of Synaptic ApS for 2022 has been prepared in accordance with the provisions in the Danish Financial Statements Act applying to reporting class B entities and elective choice of certain provisions applying to reporting class C entities.

The accounting policies used in the preparation of the financial statements are consistent with those of last year.

Reporting currency

The financial statements are presented in Danish kroner (DKK).

Foreign currency translation

On initial recognition, transactions denominated in foreign currencies are translated at the exchange rate at the transaction date. Foreign exchange differences arising between the exchange rates at the transaction date and the date of payment are recognised in the income statement as financial income or financial expenses.

Receivables and payables and other monetary items denominated in foreign currencies are translated at the exchange rate at the balance sheet date. The difference between the exchange rates at the balance sheet date and the date at which the receivable or payable arose or was recognised in the most recent financial statements is recognised in the income statement as financial income or financial expenses.

Income statement

Other operating income

Other operating income comprise items of a secondary nature relative to the Company's core activities, including gains on the sale of fixed assets.

Other external expenses

Other external expenses include the year's expenses relating to the Company's core activities, including expenses relating to distribution, advertising, administration, premises etc.

Amortisation

The item comprises amortisation of intangible assets.

The cost net of the expected residual value for completed development projects and acquired patents is amortised over the expected useful life.

The basis of amortisation, which is calculated as cost less any residual value, is amortised on a straight line basis over the expected useful life. The expected useful lives of the assets are as follows.

Patents	20 years
---------	----------

Financial expenses

Financial expenses are recognised in the income statements at the amounts that concern the financial year. Net financials include interest expenses as well as allowances and surcharges under the advance-payment-of-tax scheme, etc.

Financial statements 1 January - 31 December

Notes to the financial statements

1 Accounting policies (continued)

Tax

Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.

The Company and its Danish group entities are jointly taxed. The total Danish income tax charge is allocated between profit/loss-making Danish entities in proportion to their taxable income (full absorption).

Jointly taxed entities entitled to a tax refund are reimbursed by the management company based on the rates applicable to interest allowances, and jointly taxed entities which have paid too little tax pay a surcharge according to the rates applicable to interest surcharges to the management company.

Balance sheet

Intangible assets

Other intangible assets include development projects and patents. Development projects and patents are recognized in the balance sheet when it is probable that future economic benefits will flow to the company and the value of the asset can be measured reliably.

Intangible assets are measured at cost less accumulated amortisation and impairment losses.

Impairment of fixed assets

The carrying amount of intangible assets, property, plant and equipment and investments in subsidiaries and associates is assessed for impairment on an annual basis.

Impairment tests are conducted on assets or groups of assets when there is evidence of impairment. The carrying amount of impaired assets is reduced to the higher of the net selling price and the value in use (recoverable amount).

The recoverable amount is the higher of the net selling price of an asset and its value in use. The value in use is calculated as the present value of the expected net cash flows from the use of the asset or the group of assets and the expected net cash flows from the disposal of the asset or the group of assets after the end of the useful life.

Previously recognised impairment losses are reversed when the reason for recognition no longer exists. Impairment losses on goodwill are not reversed.

Receivables

The Company has chosen IAS 39 as interpretation for impairment write-down of financial receivables.

Receivables are measured at amortised cost.

An impairment loss is recognised if there is objective evidence that a receivable or a group of receivables is impaired. If there is objective evidence that an individual receivable has been impaired, an impairment loss is recognised on an individual basis.

Receivables in respect of which there is no objective evidence of individual impairment are tested for objective evidence of impairment on a portfolio basis. The portfolios are primarily based on the debtors' domicile and credit ratings in line with the Company's risk management policy. The objective evidence applied to portfolios is determined based on historical loss experience.

Impairment losses are calculated as the difference between the carrying amount of the receivables and the present value of the expected cash flows, including the realisable value of any collateral received. The effective interest rate for the individual receivable or portfolio is used as discount rate.

Financial statements 1 January - 31 December

Notes to the financial statements

1 Accounting policies (continued)

Cash

Cash comprise cash and short term securities which are readily convertible into cash and subject only to minor risks of changes in value.

Equity

Reserve for development costs

The reserve for development costs comprises recognised development costs. The reserve cannot be used to distribute dividend or cover losses. The reserve will be reduced or dissolved if the recognised development costs are amortised or are no longer part of the Company's operations by a transfer directly to the distributable reserves under equity.

Income taxes

Current tax payables and receivables are recognised in the balance sheet as the estimated income tax charge for the year, adjusted for prior-year taxes and tax paid on account.

Deferred tax is measured according to the liability method on all temporary differences between the carrying amount and the tax base of assets and liabilities. However, deferred tax is not recognised on temporary differences relating to goodwill which is not deductible for tax purposes and on office premises and other items where temporary differences, apart from business combinations, arise at the date of acquisition without affecting either profit/loss for the year or taxable income. Where alternative tax rules can be applied to determine the tax base, deferred tax is measured based on Management's intended use of the asset or settlement of the liability, respectively.

Deferred tax is measured according to the tax rules and at the tax rates applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the expected value of their utilisation; either as a set-off against tax on future income or as a set-off against deferred tax liabilities in the same legal tax entity. Changes in deferred tax due to changes in the tax rate are recognised in the income statement.

Other payables

Other payables are measured at net realisable value.

Financial statements 1 January - 31 December

Notes to the financial statements

2 Going concern uncertainties

Management is responsible for ensuring that the sufficient capital resources and liquidity is available to meet the Company's current and future liabilities as they fall due. To mitigate this matter, the Companys benifical owner, has pledged a declaration of resignation.

Furthermore going concern is based on further public funding or external revenue during 2023.

	DKK	2022	2021
3 Staff costs			
Wages/salaries		17,437	0
Other social security costs		189	0
		<u>17,626</u>	<u>0</u>
4 Tax for the year			
Deferred tax adjustments in the year		-124,745	-70,395
		<u>-124,745</u>	<u>-70,395</u>

5 Intangible assets

	DKK	Patents	Development projects in progress and prepayments for intangible assets	Total
Cost at 1 January 2022		287,000	319,975	606,975
Additions		<u>140,780</u>	<u>567,022</u>	<u>707,802</u>
Cost at 31 December 2022		<u>427,780</u>	<u>886,997</u>	<u>1,314,777</u>
Impairment losses and amortisation at 1 January 2022		5,000	0	5,000
Amortisation for the year		<u>5,000</u>	<u>0</u>	<u>5,000</u>
Impairment losses and amortisation at 31 December 2022		<u>10,000</u>	<u>0</u>	<u>10,000</u>
Carrying amount at 31 December 2022		<u>417,780</u>	<u>886,997</u>	<u>1,304,777</u>
Amortised over			20 years	

Development projects comprise of development cost for new technology and products. The recognition of the development projects has been made on the basis of sales forecasts which management expects to realize. The sales forecasts are subject to some uncertainty as the Company and its projects are in a start-up phase.

Financial statements 1 January - 31 December

Notes to the financial statements

6 Non-current liabilities other than provisions

Long-term other payables consist of a loan from Vækstfonden.

Of the long-term liabilities, the total amount falls due for payment within 5 years after the balance sheet date.

7 Contractual obligations and contingencies, etc.

Other financial obligations

Rent and lease liabilities include rent liabilities on DKK 9,300 with a remaining contract period of 3 months.

8 Collateral

As security for the Company's debt to thirdparties, the Company has provided security or other collateral in its assets for at total amount of DKK 1,100,000.

PENNEO

Underskrifterne i dette dokument er juridisk bindende. Dokumentet er underskrevet via Penneo™ sikker digital underskrift.
Underskrivernes identiteter er blevet registereret, og informationerne er listet herunder.

"Med min underskrift bekræfter jeg indholdet og alle datoer i dette dokument."

Eivind Antonsen Segtnan

Direktion

På vegne af: Synaptic ApS

Serienummer: PID:9208-2002-2-999131068301

IP: 212.130.xxx.xxx

2023-05-30 18:54:44 UTC

NEM ID 

Eivind Antonsen Segtnan

Dirigent

På vegne af: Synaptic ApS

Serienummer: PID:9208-2002-2-999131068301

IP: 212.130.xxx.xxx

2023-05-30 18:54:44 UTC

NEM ID 

Søren Smedegaard Hvid

Statsautoriseret revisor

På vegne af: EY Godkendt Revisionspartnerselskab

Serienummer: CVR:30700228-RID:1256831000710

IP: 2.104.xxx.xxx

2023-05-30 20:52:47 UTC

NEM ID 

Dette dokument er underskrevet digitalt via **Penneo.com**. Signeringsbeviserne i dokumentet er sikret og valideret ved anvendelse af den matematiske hashværdi af det originale dokument. Dokumentet er låst for ændringer og tidsstemplet med et certifikat fra en betroet tredjepart. Alle kryptografiske signeringsbeviser er indlejet i denne PDF, tilfældet af at de skal anvendes til validering i fremtiden.

Sådan kan du sikre, at dokumentet er originalt

Dette dokument er beskyttet med et Adobe CDS certifikat. Når du åbner dokumentet

i Adobe Reader, kan du se, at dokumentet er certificeret af **Penneo e-signature service <penneo@penneo.com>**. Dette er din garanti for, at indholdet af dokumentet er uændret.

Du har mulighed for at efterprøve de kryptografiske signeringsbeviser i ndlejret i dokumentet ved at anvende Penneos validator på følgende websted: <https://penneo.com/validator>